Migraine Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Migraine is a complex, recurring neurological disorder affecting approximately 1 billion people globally, ranking among the top three most prevalent diseases worldwide and the second leading cause of disability years. It imposes profound personal, professional, and economic burdens, with chronic forms severely impairing quality of life.

ICHD-3 Diagnostic Criteria

The International Classification of Headache Disorders, 3rd Edition (ICHD-3), published by the International Headache Society (IHS), defines migraine without aura (the most common form) as:

• At least 5 attacks fulfilling criteria B–D
• Headache lasting 4–72 hours (untreated or unsuccessfully treated)
• At least 2 of the following 4 characteristics: unilateral location, pulsating quality, moderate or severe pain intensity, aggravation by or causing avoidance of routine physical activity
• During headache, at least 1 of the following: nausea and/or vomiting; photophobia and phonophobia
• Not better accounted for by another ICHD-3 diagnosis

Migraine with aura additionally requires ≥1 fully reversible aura symptom (visual, sensory, speech/language, motor, brainstem, retinal) developing over 5–20 minutes and lasting <60 minutes.

Chronic vs Episodic Migraine

Episodic migraine: fewer than 15 headache days/month. Chronic migraine is defined as ≥15 headache days/month for >3 months, with at least 8 days fulfilling migraine criteria. Chronic migraine affects approximately 2% of the global population and is strongly associated with medication overuse headache (MOH), depression, anxiety, and sleep disorders.

Pathophysiology

Current evidence supports the trigeminovascular hypothesis: activation of trigeminal nerve fibres innervating intracranial blood vessels leads to release of calcitonin gene-related peptide (CGRP) and other neuropeptides, causing neurogenic inflammation and central sensitisation. CGRP levels are elevated during attacks and normalise with successful treatment — this discovery underpins the revolution in migraine-specific preventive therapy. Cortical spreading depression (CSD) — a slow wave of neuronal depolarisation — is the neurophysiological correlate of the migraine aura.

Modern migraine treatment pathways address the full spectrum of migraine disorders as classified by ICHD-3:

• Episodic migraine without aura: The most common form; managed primarily with acute (abortive) therapy. Preventive therapy initiated if ≥4 days/month with disability.
• Episodic migraine with aura: Aura symptoms must be distinguished from transient ischaemic attack (TIA), particularly for new-onset cases. Combined oral contraceptives are contraindicated due to stroke risk. Triptans should not be used during the aura phase.
• Chronic migraine (CM): Defined as ≥15 headache days/month (≥8 migraine days). Requires preventive therapy; OnabotulinumtoxinA and CGRP monoclonal antibodies are FDA-approved specifically for CM.
• Menstrual migraine: Attacks occurring exclusively ±2 days around menstruation; managed with perimenstrual mini-prophylaxis (triptans or frovatriptan) or continuous combined oral contraceptives.
• Medication overuse headache (MOH): Rebound headache from overuse of acute medications (>10 days/month for triptans/opioids; >15 days/month for simple analgesics). Requires detoxification and transition to preventive therapy.
• Vestibular migraine: Episodic vestibular symptoms (dizziness, vertigo) meeting migraine criteria; treated with migraine-specific medications including CGRP mAbs.
• Hemiplegic migraine: Rare form with motor aura; triptans and ergotamines are contraindicated. Management involves verapamil or flunarizine prophylaxis.

All patients with confirmed migraine diagnosis require a structured management plan. Treatment intensity is stratified by attack frequency and disability:

Acute Therapy (All Patients)

Every patient with confirmed migraine should have an established acute treatment plan, including first-line agents and rescue options, discussed with their clinician.

Preventive Therapy Indications

The American Headache Society (AHS) and European Headache Federation (EHF) recommend considering preventive therapy when:

• ≥4 migraine days/month causing significant disability
• Acute medications are contraindicated, ineffective, or being overused
• Migraine significantly impairs daily functioning despite acute treatment
• Patient preference for reduced attack burden
• Special circumstances: hemiplegic migraine, migraine with prolonged aura, frequent aura without headache

Criteria Favouring CGRP Monoclonal Antibodies

• Failure of ≥2 oral preventives (per NICE guidance; ≥2–4 per FDA label)
• High migraine frequency (≥8 migraine days/month preferred by payers)
• Intolerance to conventional preventives
• Chronic migraine requiring specific CM-approved therapies

Red Flags Requiring Urgent Assessment

SNOOP4 criteria: Systemic symptoms, Neurological symptoms, Onset sudden (thunderclap), Onset after age 50, Progressive worsening, Postural component, Papilloedema, Prior history change. Any of these warrants urgent neuroimaging before attributing headache to migraine.

Migraine management is divided into acute (abortive) therapy — treating individual attacks — and preventive (prophylactic) therapy — reducing attack frequency, severity, and duration over time.

Acute Therapies

Triptans (5-HT1B/1D Agonists) — First-Line Migraine-Specific Acute Therapy

Triptans are the gold standard for moderate-to-severe migraine attacks. They act as selective serotonin receptor agonists causing cranial vasoconstriction and blocking trigeminal neuropeptide release:

• Sumatriptan: Oral 50–100 mg, subcutaneous 6 mg (fastest onset; NNT ~2.5 for 2-hour pain freedom), nasal spray 10–20 mg. First triptan approved; widely available as generic.
• Rizatriptan: Oral 10 mg or wafer (orally disintegrating); onset 30–45 minutes; consistently high efficacy in trials.
• Eletriptan: Oral 40–80 mg; high lipophilicity; often preferred for better sustained pain freedom.
• Zolmitriptan: Oral 2.5–5 mg or nasal spray 5 mg; nasal route bypasses absorption issues in attacks with nausea.
• Almotriptan, frovatriptan, naratriptan: Longer half-lives (especially frovatriptan ~26h) make them useful for menstrual migraine prevention or when recurrence is a problem.

Triptans are contraindicated in: ischaemic heart disease, uncontrolled hypertension, stroke/TIA history, Prinzmetal angina, hemiplegic/basilar migraine, and pregnancy (relative).

CGRP Receptor Antagonists — Gepants (Acute Use)

Gepants represent a breakthrough class that blocks the CGRP receptor without vasoconstriction, making them suitable for patients with cardiovascular contraindications to triptans:

• Ubrogepant (Ubrelvy): 50 mg or 100 mg orally; FDA-approved 2019. In the ACHIEVE I and ACHIEVE II trials, 19.2% and 21.8% of patients achieved 2-hour pain freedom vs 11.9% and 14.3% for placebo.
• Rimegepant (Nurtec ODT): 75 mg orally disintegrating tablet; FDA-approved 2020. Unique in having dual approval for both acute treatment and preventive therapy (every-other-day dosing for prevention).

5-HT1F Agonist — Lasmiditan (Reyvow)

Lasmiditan selectively binds the 5-HT1F receptor with no vasoconstrictive activity, making it the first neurally acting acute migraine therapy. FDA-approved at 50 mg and 100 mg. Key limitation: central nervous system (CNS) side effects (dizziness, somnolence) and a mandatory 8-hour no-driving restriction after use. Approved as a Schedule V controlled substance.

Non-Specific Acute Treatments

• NSAIDs: Ibuprofen 400–600 mg, naproxen sodium 550 mg, or aspirin 1000 mg — effective for mild-to-moderate attacks; less effective for severe attacks. Risk of MOH with frequent use.
• Antiemetics: Metoclopramide 10 mg (also improves gastric motility, enhancing absorption of co-administered analgesics), prochlorperazine, ondansetron — used adjunctively or in patients with prominent nausea.
• Ergotamines: Largely superseded by triptans; retained for refractory attacks or when recurrence within 24 hours is a particular issue. DHE (dihydroergotamine) via nasal spray or IV infusion retains a clinical role in status migrainosus.

Preventive (Prophylactic) Therapies

Conventional Oral Preventives (First-Line)

• Topiramate (Topamax): 50–100 mg/day; Level A evidence; NNT for 50% responder rate ~3.5. Side effects: cognitive slowing ('dopamax'), paresthesias, weight loss, teratogenicity — absolutely contraindicated in pregnancy.
• Propranolol: 40–240 mg/day; beta-blocker; Level A evidence. Contraindicated in asthma, COPD, bradycardia, diabetes. Also timolol, metoprolol, atenolol.
• Amitriptyline: 10–75 mg nightly; Level A evidence; particularly useful in comorbid depression, anxiety, or insomnia. Anticholinergic side effects (dry mouth, constipation, urinary retention).
• Valproate/valproic acid: Level A; teratogenic — absolutely contraindicated in women of childbearing potential. Risk of foetal valproate syndrome.
• Venlafaxine: 75–150 mg/day; Level B evidence; useful when comorbid depression is present.
• Candesartan/lisinopril: Level B evidence; well tolerated; useful alternatives when beta-blockers are contraindicated.
• Flunarizine: Calcium channel blocker available in Europe and Asia; Level A evidence; not available in the US.

CGRP Monoclonal Antibodies (mAbs) — Disease-Modifying Prevention

Anti-CGRP and anti-CGRP receptor mAbs represent the first preventive treatments developed specifically for migraine. Four are approved:

• Erenumab (Aimovig) — anti-CGRP receptor: 70 mg or 140 mg subcutaneous monthly. ARISE trial (70 mg): mean monthly migraine day (MMD) reduction 2.9 days vs 1.8 placebo. STRIVE trial (140 mg): 3.7 day reduction. 50% responder rates 39.7% (70 mg) and 43.3% (140 mg) vs 26.6% placebo.
• Fremanezumab (Ajovy) — anti-CGRP ligand: 225 mg monthly or 675 mg quarterly subcutaneous. HALO CM trial (chronic migraine): 4.6–4.9 day reduction in monthly headache days. HALO EM trial (episodic): 3.4–3.7 day MMD reduction.
• Galcanezumab (Emgality) — anti-CGRP ligand: 240 mg loading dose then 120 mg monthly subcutaneous. EVOLVE-1 and EVOLVE-2 trials (episodic): 4.7 day MMD reduction (120 mg). REGAIN trial (chronic): 4.8 day reduction. 50% responder rates 59–62% in episodic migraine trials.
• Eptinezumab (Vyepti) — anti-CGRP ligand: First IV-administered mAb; 100 mg or 300 mg quarterly infusion. PROMISE-1 (episodic) and PROMISE-2 (chronic) trials demonstrated effect onset within 1 day of infusion. 50% responder rates 49.8% (PROMISE-1, 300 mg) and 61% (PROMISE-2, 300 mg, chronic migraine).

Class-wide 50% responder rates across pivotal trials: approximately 50–60% vs 25–35% for placebo. Side effects are generally mild (injection site reactions, constipation with erenumab). No hepatotoxicity or teratogenicity signals to date — though use in pregnancy is not recommended due to limited data.

OnabotulinumtoxinA (Botox) — PREEMPT Protocol

FDA-approved for chronic migraine only (not episodic), based on the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) program (two RCTs, n=1,384 combined):

• Protocol: 155–195 units injected across 31–39 sites in a fixed-site, fixed-dose paradigm
• Sites: corrugator, procerus, frontalis, temporalis, occipitalis, cervical paraspinals, trapezius bilaterally
• Administered every 12 weeks (3-month cycles)
• PREEMPT 1 and 2 combined: reduction in headache days of 8.4 (botox) vs 6.6 (placebo) over 24 weeks
• Onset of benefit may require 2–3 treatment cycles
• Well tolerated; most common adverse effects: neck pain, injection site pain, headache, blepharoptosis

Neuromodulation Devices

• Cefaly (supraorbital transcutaneous electrical nerve stimulation): CE-marked and FDA-cleared for both acute and preventive migraine. External device worn on forehead that stimulates the supraorbital branch of the trigeminal nerve. PREMICE trial: 38.3% responder rate (vs 12.1% sham).
• Nerivio (remote electrical neuromodulation): FDA-cleared wearable arm device. Activates conditioned pain modulation (CPM) via the periaqueductal grey. ACME trial: 66.7% experienced pain relief at 2 hours (vs 38.8% sham).
• gammaCore (non-invasive vagus nerve stimulation): FDA-cleared for acute and preventive treatment in episodic cluster headache and acute migraine.
• SpringTMS (single-pulse transcranial magnetic stimulation): FDA-cleared for migraine with aura; applied at aura onset.

A well-designed migraine management plan delivers measurable, validated improvements across multiple domains:

• Acute treatment success: First-line triptan therapy achieves 2-hour pain freedom in 25–42% of patients and 2-hour pain relief (moderate-to-none) in 57–77%. CGRP antagonists (gepants) achieve comparable or slightly lower acute efficacy but broader safety profiles.
• Preventive therapy responder rates: Conventional preventives (topiramate, propranolol) achieve ≥50% reduction in MMDs in approximately 35–45% of patients. CGRP mAbs achieve 50–60% responder rates — a significant advance over prior standard of care.
• Improvement in migraine disability (MIDAS score): CGRP mAb pivotal trials demonstrated consistent, clinically meaningful reductions in MIDAS scores alongside headache day reductions.
• Prevention of medication overuse: Effective preventive therapy reduces reliance on acute medications, thereby reducing MOH risk — a critical secondary benefit.
• Sustained efficacy: Open-label extension studies for CGRP mAbs demonstrate maintained benefit over 12–36 months of continuous use, with some patients achieving sustained remission following treatment discontinuation.
• Chronic migraine conversion: OnabotulinumtoxinA and CGRP mAbs can convert some patients from chronic to episodic migraine over time — a clinically meaningful endpoint.

Each treatment class carries distinct safety considerations:

Triptans

• Cardiovascular contraindications (ischaemic heart disease, uncontrolled hypertension, stroke history) due to vasoconstrictive mechanism
• Triptan sensations: chest tightness, flushing, neck stiffness — usually benign but can alarm patients
• Medication overuse headache if used >10 days/month
• Serotonin syndrome risk if combined with serotonergic medications (SSRIs, SNRIs) — though clinically rare at therapeutic doses

CGRP Antagonists (Gepants)

• Generally well tolerated; nausea and fatigue most common
• Potential drug interactions via CYP3A4 (ubrogepant) or P-gp/BCRP transporters
• Avoid in severe hepatic impairment
• Limited long-term safety data beyond 12 months

Conventional Preventives

• Topiramate: Cognitive side effects ('dopamax' — word-finding difficulty, slowed thinking), paresthesias, weight loss, kidney stones, acute glaucoma, severe teratogenicity (Category D — neural tube defects, cleft palate)
• Valproate: Absolutely contraindicated in pregnancy and women of childbearing potential due to foetal valproate syndrome. Hepatotoxicity, weight gain, hair loss, tremor.
• Amitriptyline: Sedation, anticholinergic effects, QTc prolongation risk at higher doses, weight gain
• Beta-blockers: Contraindicated in asthma, COPD, bradyarrhythmias, peripheral vascular disease; can cause fatigue, depression, sexual dysfunction

CGRP Monoclonal Antibodies

• Most common: injection site reactions (erythema, pain), constipation (particularly erenumab — CGRP regulates bowel motility)
• No evidence of hepatotoxicity or immunogenicity-related safety signals in 3+ years of post-marketing surveillance
• Avoid in pregnancy and breastfeeding (no adequate data)
• High cost may limit access without specialist prescribing and insurer prior authorisation

OnabotulinumtoxinA

• Neck pain, injection site discomfort, blepharoptosis, eyebrow asymmetry (usually transient)
• Distant spread of toxin effect (rare) — swallowing difficulty, weakness
• Contraindicated in neuromuscular junction disorders (myasthenia gravis)

Migraine management requires ongoing monitoring and treatment optimisation rather than a single intervention:

Headache Diary

All patients should maintain a prospective headache diary (paper or digital app) recording: date and time of onset, duration, severity (0–10 NRS), associated symptoms, acute medications used, response to treatment, menstrual cycle (women), potential triggers. At least 4 weeks of diary data are recommended before initiating preventive therapy, and ongoing diary use allows objective assessment of treatment response.

Preventive Therapy Monitoring

• Conventional preventives: reassess after 8–12 weeks at therapeutic dose. Adequate trial is minimum 3 months. If <25% reduction in MMDs at 3 months, consider switching.
• CGRP mAbs: reassess at 3 months. Most responders demonstrate ≥50% MMD reduction by month 3. Some patients with partial responses at 3 months continue to improve at 6 months. Annual review of continued need recommended.
• OnabotulinumtoxinA: reassess after 2–3 treatment cycles (6–9 months). If no clinically meaningful response after 3 cycles, discontinue.

Medication Overuse Screening

Monitor acute medication usage at every visit. Overuse (>10 days/month for triptans or opioids; >15 days/month for simple analgesics over >3 months) requires withdrawal of the overused medication. Brief detoxification (abrupt withdrawal in most cases) with bridge therapy (CGRP mAb, naproxen, prednisone taper) significantly improves preventive therapy outcomes.

Comorbidity Management

Migraine is strongly associated with depression, anxiety, sleep disorders, and epilepsy. Integrated management of comorbidities — and choosing preventives that address both migraine and the comorbidity (e.g., amitriptyline for migraine + depression; valproate for migraine + epilepsy in appropriate patients) — improves overall outcomes.

Specialist Referral

Refer to a neurologist or headache specialist for: diagnostic uncertainty, failure of ≥2 preventive agents, chronic migraine, medication overuse, consideration of CGRP mAbs or OnabotulinumtoxinA, new or changed headache pattern, or any red flag features.

Migraine treatment costs span a wide range depending on the therapeutic approach:

Acute Medications

• Generic triptans (sumatriptan, rizatriptan): USD 5–30 per tablet (generic); often covered by insurance after tier authorisation
• Gepants (ubrogepant, rimegepant): Approximately USD 800–1,000/month list price; manufacturer copay cards available in the US; limited generic availability as of 2026
• Lasmiditan: Approximately USD 900–1,100/month list price; schedule V classification may affect prescribing patterns

Preventive Medications

• Conventional preventives (topiramate, propranolol, amitriptyline): USD 5–30/month generic — highly cost-effective first-line options
• CGRP monoclonal antibodies: List price USD 600–800/month in the US; EUR 400–700/month in Europe. Significant out-of-pocket costs without insurance. Manufacturer patient assistance programmes available. In India and developing markets, these agents are priced USD 150–400/month where available.

OnabotulinumtoxinA (PREEMPT)

• USD 300–600 per vial (100 unit vials); procedure requires 2–3 vials per treatment session
• Administration fee: USD 200–400 per session
• Total per session: USD 1,000–2,500 every 12 weeks; typically requires prior authorisation demonstrating chronic migraine diagnosis and failure of ≥2 oral preventives

Neuromodulation Devices

• Cefaly: Approximately USD 400–600 device cost; prescription required
• Nerivio: Subscription-based model, approximately USD 99–199/month in the US

Global Treatment Access

In low- and middle-income countries, CGRP mAbs and neuromodulation devices have limited availability and affordability. Evidence-based generic preventives (topiramate, propranolol, amitriptyline, flunarizine) remain the foundation of preventive care globally and are highly effective when properly titrated.

Evidence-based non-pharmacological strategies play an important adjunctive role and can reduce reliance on medications:

Lifestyle and Trigger Management

• Sleep hygiene: Maintaining consistent sleep/wake times reduces attack frequency. Both sleep deprivation and excessive sleep are common triggers.
• Hydration: Dehydration is a recognised trigger; adequate daily fluid intake is recommended.
• Regular meals: Fasting and skipping meals trigger attacks in many patients.
• Exercise: Regular aerobic exercise 3x/week has Level B evidence for migraine prevention. Paradoxically, intense exercise can trigger attacks — graduated intensity increases are recommended.
• Trigger identification: Common triggers include stress, hormonal changes, alcohol (particularly red wine), bright light, strong odours, and weather changes. However, not all triggers are avoidable, and excessive trigger avoidance can impair quality of life.

Behavioural and Psychological Therapies

• Cognitive behavioural therapy (CBT): Level A evidence for migraine prevention — reduces attack frequency and improves disability scores; enhances efficacy of pharmacological therapy when combined.
• Biofeedback: Particularly electromyographic (EMG) biofeedback; Level A evidence; reduces headache frequency and medication use. Available as app-based products.
• Mindfulness-based stress reduction (MBSR): Level B evidence; benefit demonstrated in chronic migraine specifically.
• Relaxation training: Progressive muscle relaxation; Level A evidence when used alone or with biofeedback.

Nutraceuticals

• Magnesium (400–600 mg/day oral): Level B evidence for prevention; particularly in menstrual migraine and migraine with aura. Commonly recommended for patients reluctant to start prescription medications.
• Riboflavin (vitamin B2, 400 mg/day): Level B evidence; well tolerated; may take 3 months to show benefit.
• Coenzyme Q10 (300 mg/day): Level C evidence; antioxidant mechanism.
• Melatonin (3 mg nightly): Level B evidence; particularly relevant when sleep disturbance is prominent.

Acupuncture

Cochrane reviews (Linde et al., 2016) found acupuncture to be at least as effective as prophylactic drug treatment in reducing migraine frequency, with fewer side effects. Considered a valid alternative for patients who prefer non-pharmacological approaches or have contraindications to preventive medications.